GlaxoSmithKline and Gilead Sciences will be showcasing rival strategies for fighting the AIDS virus at next month’s global AIDS conference.
ViiV Healthcare, a joint effort between GSK and Pfizer, will be presenting detailed trial results from its new two-drug treatment combining dolutegravir (Tivicay) and lamivudine (Epivir), after announcing last week that the studies met primary endpoints.
Gilead, currently with an AIDS market share of 52 percent versus GSK’s 22 percent, will stick with the industry standard three-drug combinations. Gilead’s Biktarvy, a triple-therapy, single-tablet drug to treat HIV, was cleared for sale in the U.S. in February. A month later, Gilead released data from a head-to-head clinical trial showing that Biktarvy is noninferior to a treatment containing Tivicay and Epivir, plus another ViiV drug, Ziagen.
Read the Reuters coverage